Approved (FDA)

FDA Clears ARCUS Editor for Duchenne Hot-spot
CMN Clinical

Feb. 18, 2026

The US FDA has issued a Study May Proceed notification for PBGENE-DMD, Precision BioSciences' investigational in vivo gene-editing therapy for...

Clinical Trial Update – CRISPR-Based Diagnostics...
Oct. 28, 2020

We have added three clinical trials to our comprehensive database of the current CRISPR-based trials for gene-editing therapies and diagnostics. This...

The world’s first FDA-authorized CRISPR...
May. 21, 2020

For the first time, the FDA has authorized a CRISPR gene-editing tool - the COVID 19 diagnostic kit developed by Sherlock Biosciences, here CEO Rahul...

Approved (FDA)

B-Cell Non-Hodgkin Lymphoma, NHL, (NCT04649112)
Sponsors:
Precision BioSciences Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Disease, SCD, (NCT04819841)
Sponsors:
Kamau Therapeutics
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Renal Cell Carcinoma, RCC, (NCT04696731)
Sponsors:
Allogene Therapeutics, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory Acute Myeloid Leukaemia, AML, and Multiple Myeloma, MM, (NCT04614636)
Sponsors:
Fate Therapeutics, Inc
Indicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory B-Cell Malignancies, (NCT04629729)
Sponsors:
Fate Therapeutics
Indicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, B-NHL, (NCT04637763)
Sponsors:
Caribou Biosciences, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory Multiple Myeloma, MM, (NCT04171843)
Sponsors:
Precision BioSciences, Inc.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory Lymphoma and Leukaemia, (NCT04030195)
Sponsors:
Precision BioSciences, Inc.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
close
Search CRISPR Medicine